Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The Medicare GLP-1 Bridge took effect July 1, 2026, and we are scheduling Medicare eligibility visits now
Researchers have observed that patients prescribed semaglutide, the active ingredient in both drugs, had an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION)
There have been periodic shortages on Zepbound since 2022
Patients should be aware that severe or progressive cold intolerance especially when accompanied by significant fatigue, constipation, dry skin, hair loss, or unexplained weight gain despite continued GLP-1 therapywarrants investigation for hypothyroidism or other conditions
Semaglutide presents an exciting new option for individuals struggling with weight loss, offering significant potential benefits in terms of effective weight reduction and improved glycemic control
US$ 29.82
US$ 20.58
US$ 22.27
US$ 24.96
US$ 28.60
US$ 26.78
